Synthesis of complex and diverse compounds through ring distortion of abietic acid.

Many compound screening collections are populated by members that possess a low degree of structural complexity. In an effort to generate compounds that are both complex and diverse, we have developed a strategy that uses natural products as a starting point for complex molecule synthesis. Herein we apply this complexity-to-diversity approach to abietic acid, an abundant natural product used commercially in paints, varnishes, and lacquers. From abietic acid we synthesize a collection of complex (as assessed by fraction of sp(3) -hybridized carbons and number of stereogenic centers) and diverse (as assessed by Tanimoto analysis) small molecules. The 84 compounds constructed herein, and those created through similar efforts, should find utility in a variety of biological screens.

[1]  F. Lovering,et al.  Escape from Flatland 2: complexity and promiscuity , 2013 .

[2]  R. Hicklin,et al.  A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. , 2013, Nature chemistry.

[3]  Kieron M. G. O'Connell,et al.  A two-directional strategy for the diversity-oriented synthesis of macrocyclic scaffolds. , 2012, Organic & biomolecular chemistry.

[4]  David R Spring,et al.  Diversity-oriented synthesis: producing chemical tools for dissecting biology. , 2012, Chemical Society reviews.

[5]  Stefan Wetzel,et al.  Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.

[6]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[7]  Jeffrey Aubé,et al.  Small-molecule libraries: naturally inspired oligomers. , 2012, Nature chemistry.

[8]  M. J. Chalmers,et al.  A Biomimetic Polyketide-Inspired Approach to Small Molecule Ligand Discovery , 2011, Nature chemistry.

[9]  R. Chahboun,et al.  Lead(IV) acetate mediated cleavage of β-hydroxy ethers: enantioselective synthesis of α-acetoxy carbonyl compounds , 2011 .

[10]  S. Wetzel,et al.  Biologie‐orientierte Synthese (BIOS) , 2011 .

[11]  Stefan Wetzel,et al.  Biology-oriented synthesis. , 2011, Angewandte Chemie.

[12]  J. Porco,et al.  Remodeling of the Natural Product Fumagillol Employing a Reaction Discovery Approach , 2011, Nature Chemistry.

[13]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[14]  A. Papavassiliou,et al.  Tackling transcription factors: challenges in antitumor therapy. , 2011, Trends in molecular medicine.

[15]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[16]  P. Hergenrother,et al.  High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies. , 2011, Chemical Society reviews.

[17]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[18]  Jie Liang,et al.  Creation and manipulation of common functional groups en route to a skeletally diverse chemical library , 2011, Proceedings of the National Academy of Sciences.

[19]  Eamon Comer,et al.  Fragment-based domain shuffling approach for the synthesis of pyran-based macrocycles , 2011, Proceedings of the National Academy of Sciences.

[20]  V. Setola,et al.  Synthesis and receptor profiling of Stemona alkaloid analogues reveal a potent class of sigma ligands , 2011, Proceedings of the National Academy of Sciences.

[21]  L. Silver.  Challenges of Antibacterial Discovery , 2011, Clinical Microbiology Reviews.

[22]  Sivaraman Dandapani,et al.  Grand challenge commentary: Accessing new chemical space for 'undruggable' targets. , 2010, Nature chemical biology.

[23]  David R Spring,et al.  Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. , 2010, Nature communications.

[24]  C. Galmarini,et al.  A Review of Trabectedin (ET-743): A Unique Mechanism of Action , 2010, Molecular Cancer Therapeutics.

[25]  Yuanchao Li,et al.  Efficient synthesis of the key intermediate triptophenolide methyl ether for the synthesis of (-)-triptolide , 2010 .

[26]  M. Hahn,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[27]  D. Ferraris,et al.  Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. , 2010, Journal of medicinal chemistry.

[28]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[29]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[30]  R. H. Baltz.  Renaissance in antibacterial discovery from actinomycetes. , 2008, Current opinion in pharmacology.

[31]  Alexander Dömling,et al.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? , 2008, Current opinion in chemical biology.

[32]  H. Moser,et al.  Physicochemical properties of antibacterial compounds: implications for drug discovery. , 2008, Journal of medicinal chemistry.

[33]  R. Chahboun,et al.  Regioselective routes towards 14-hydroxyabietane diterpenes. A formal synthesis of immunosuppressant (−)-triptolide from (+)-abietic acid , 2007 .

[34]  J. Yadav,et al.  Synthesis of (+)-amberketal and its analog from l-abietic acid , 2007 .

[35]  M. Lachkar,et al.  First synthesis of picealactone C. A new route toward taxodione-related terpenoids from abietic acid , 2007 .

[36]  T. Kirchhausen,et al.  Synthesis of a 10,000-membered library of molecules resembling carpanone and discovery of vesicular traffic inhibitors. , 2006, Journal of the American Chemical Society.

[37]  A. Schuffenhauer,et al.  Complex molecules: do they add value? , 2005, Current opinion in chemical biology.

[38]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[39]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[40]  Johann Gasteiger,et al.  Prediction of Aqueous Solubility of Organic Compounds Based on a 3D Structure Representation , 2003, J. Chem. Inf. Comput. Sci..

[41]  Y. Feng,et al.  Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. , 2001, Journal of the American Chemical Society.

[42]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[43]  P. Bartlett,et al.  Synthetic strategies in combinatorial chemistry. , 1997, Current opinion in chemical biology.

[44]  U. Flörke,et al.  Untersuchung der allergenen Prinzipien aus Kolophonium: Autoxidation, Synthese und Sensibilisierung , 1992 .

[45]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[46]  D J Rogers,et al.  A Computer Program for Classifying Plants. , 1960, Science.

[47]  H. Zeiss.  The chemistry of the resin acids. , 1948, Chemical reviews.

[48]  W. Sandermann,et al.  Zur Chemie der Harze, II. Mitteil.: Anlagerungsfähigkeit der Kiefernharzsäuren , 1936 .

[49]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[50]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[51]  R. C. Cambie,et al.  Acid-Promoted Fries Rearrangements of Benzannulated Lactones , 1998 .

[52]  M. Ohno,et al.  Synthesis of (-)-ambrox from ℓ-abietic acid , 1987 .

[53]  M. Ohno,et al.  Synthesis of (−)-Warburganal and 4α-methoxycarbonyl congener from 1-abietic acid , 1982 .